Suzetrigine - Vertex Pharmaceuticals
Alternative Names: VX-548Latest Information Update: 22 Apr 2024
At a glance
- Originator Vertex Pharmaceuticals
- Class 1 ring heterocyclic compounds; Amides; Analgesics; Ethers; Fluorinated hydrocarbons; Fluorobenzenes; Pyridines; Small molecules
- Mechanism of Action Nav1.8 voltage-gated sodium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Acute pain
- Phase II Neuropathic pain; Radiculopathy
- Phase I Pain
Most Recent Events
- 18 Apr 2024 Vertex Pharmaceuticals announces intention to complete the submit of rolling NDA to the US FDA for Acute pain by the second quarter of 2024
- 18 Apr 2024 Vertex Pharmaceuticals plans two pivotal phase III trials for diabetic peripheral neuropathy in second half of 2024
- 02 Apr 2024 Vertex Pharmaceuticals plans a phase I trial in Pain (PO) (NCT06336096)